Neotrofin for Treatment of Chemotherapy-Induced Peripheral Neuropathy

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study will assess the safety and efficacy of Neotrofin in treating the peripheral neuropathy that results from chemotherapy for cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: NeoTherapeutics

Criteria

• Patient must have diagnosis of cancer and be receiving or have received chemotherapy that has resulted in sensory or motor neuropathy.

• Sensory or motor neuropathy must be >/= grade 2 per Common Toxicity Criteria at baseline.

• In patients diagnosed with multiple myeloma, grade 1 sensory or motor neuropathy is acceptable.

• Patient must have normal hematological cell counts.

• Patient must have a life expectancy of >/= 3 months.